ProLung is a privately funded medical device company that has developed and tested its novel non-invasive early diagnostics of lung cancer to save or extend lives through the early risk stratification of lung cancer. Our mission is to bring immediate non-invasive help to patients and physicians in life threatening disease and to provide a fair return on investment to shareholders and other stakeholders.
Steven C. Eror
Chief Executive Officer, President, Director
Mr. Eror cofounded ProLung and became CEO, President and Director in February 2005. During his career he served as CEO of MacroMed, Inc, (injectable and oral drug delivery, breast and esophageal cancer therapeutics, analgesics and immunotherapy) where he established licenses with Abbott, BMS and Diatos. He served as the CEO at Consonus (IT application service provider). He also has served as the CFO of Pharmadigm (injectable anti-inflammatory for severe burn, asthma and wound healing). Earlier in his career, he served as the CFO of Evans and Sutherland Computer Corporation. In addition, he has held senior development, financial and management positions at Guardian Industries, Air Products and Chemicals and Ford Motor Company. Mr. Eror holds a BA in Economics and French and an MBA from the University of Utah.
Michael A. Garff
Chief Operating Officer
Mr. Garff joined ProLung as the Chief Operating Officer in June 2009 from the Pierre Lassonde Entrepreneur Center where he served as a Director. While there he helped to launch several biomedical and energy companies. His passion for technology and experience with commercialization gives him uncommon perspective in manufacturing, training, supply and regulatory businesses. Previously, Mr. Garff earned a reputation as an organization builder and effective project manager at US Bank. He holds a BS in Business and an MBA from the University of Utah.
Jeff O’Driscoll, MD
Chief Medical Officer, Director
Jeffery S. O’Driscoll, MD, has been treating patients in the emergency department for over 20 years. He practices at a level-1 trauma center and teaching hospital, where he served as the chair of emergency medicine for eight years. Doctor O’Driscoll is board certified in internal medicine and is a fellow of the American College of Emergency Physicians. He is presently the medical director and consultant to Intermountain Healthcare’s Emergency Department Development Team and Emergency Physician Information Systems Advisory Group. He has previously chaired a regional pharmacy and therapeutics committee for Intermountain Healthcare and served on their corporate pharmacy and therapeutics committee.
Chairman of the Board of Directors
Mr. Morgan serves as the Chairman of the Board of ProLung. He began his career with The West Bend Company in the sales department and served as the District Manager. He started Morgan Industries, an asphalt paving and maintenance business, growing it from one employee to 150 employees with offices in Utah and Arizona and contracting in 7 western states. He then started NuRock, a company which manufactures asphalt maintenance products. Mr. Morgan formed MPM Investment Group LP and he currently serves as general partner and manager. He served on the Board of Directors of America West Bank. He also is a member of the Board of Directors of Ellison Ranching Company.
Robin L. Smith, MD, MBA
Dr. Robin Smith has served has President of Stem for Life Foundation since 2007. From 2003 through 2006, Dr. Smith as an advisor to various private and public companies. From 2000 through 2003, she was the President and CEO of IP2M, Inc., and from 1998 through 2000, she was the Chief Medical Officer at HealthHelp Network, Inc. Dr. Smith was the Associate Medical Director of Aetna-U.S. Healthcare from 1996 through 1997. Dr. Smith serves on the Board of Directors of Rockwell Medical Inc. (NASDAQ: RMTI), BioXCel Corporation, MyND Analytics (formerly CNS Response) and Caladrius Biosciences NASDAQ: CLBS). Dr. Smith earned a B.A. from Yale University, an MBA from The Wharton School University of Pennsylvania, and an M.D. from Yale University School of Medicine.
Richard B. (Rich) McKeown
Mr. McKeown servers as a Director of ProLung. He is currently the Chief Executive Officer and co-founder of Leavitt Partners, a health intelligence firm. During his career he served as Chief of Staff for the U.S. Department of Health & Human Services, U.S. Environmental Protection Agency. Prior to that, Mr. McKeown served as Chief of Staff to then Governor of Utah, Mike Leavitt and was also the Commission & Chairman at the Utah State Tax Commission. He and Mike Leavitt are co-authors of “Finding Allies, Building Alliances”, a book that chronicles their expertise and passion for collaboration. He completed his B.S. from Ohio University and his J.D. from the University of Utah, College of Law.
Robert W. Raybould
Mr. Raybould serves as a Director of ProLung. He began his career serving in the U.S. Army and then with Eastman Kodak in Rochester, New York. He then co-founded Realvest, a real estate investment company. Mr. Raybould has helped found several financial companies including TRI Capital Corporation, DTM Research, and Greenhill Financial, which became Arlington Value Capital, LLC. Mr. Raybould holds a BS in Banking and Finance as well as an MBA from the University of Utah.
John C. Ruckdeschel, MD
John C. Ruckdeschel, MD, is a renowned oncologist with a career-long focus on thoracic malignancies and lung cancer. He is the former Medical Director of Clinical Oncology at Intermountain Healthcare and CEO of Moffitt Cancer Center. Dr. Ruckdeschel received his B.S. degree in Biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in New York. He trained as an intern at John Hopkins Medical Center, fulfilled a residency at Boston’s Beth Israel Hospital and completed a fellowship at the National Cancer Institute in Washington D.C. He is a fellow of the American College of Physicians as well as the American College of Chest Physicians.
Clark A. Campbell
Dr. Campbell serves as a Director of ProLung. He is the Founder and CEO of OPPM International. He is the author of 4 books published by John Wiley & Sons. He was the Project Leader for the Romney Readiness Project. During his 30 year association with OC Tanner, he served as the Director of Corporate Planning, Vice President of Quality and as the Senior Vice President of Administration and Professional Services. Earlier in his career he held positions with DuPont and Northwest Pipeline. He was an Adjunct Professor at the University of Delaware, the University of Utah and Westminster College. He served on the University of Utah Alumni Board, the Shingo Prize for Operational Excellence Board of Governors and the Utah March of Dimes Board. Dr. Campbell holds a BS in Chemical Engineering and an MBA from the University of Utah.
J. Scott Nixon, CPA
J. Scott Nixon, CPA retired in 2015 as a partner with PricewaterhouseCoopers (PwC) where he spent over 31 years in various roles including Office Managing Partner and engagement partner over public and private companies in many industries. His career involved providing audit and business advisory services, was involved in numerous complex filings with the SEC, and was instrumental in resolving unique accounting issues with the SEC on behalf of his clients. In 2007, Scott returned from a four-year assignment in São Paulo, Brazil where he represented various interests of the PwC global firm to the 18 member firms in South and Central America, and led the implementation and compliance of the Sarbanes-Oxley requirements in those countries. Scott serves on several boards of directors and is a National Association of Corporate Directors (NACD) Governance Fellow. He holds both a BA and Master of Accounting from Utah State University.
Corporate Code of Conduct
The Company has adopted the Code of Ethics for Senior Executives, Financial Officers, Members of the Management Executive Committee, and Directors, which constitutes a code of ethics that applies to the principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions, as defined in Item 406 of Regulation S-K under the Exchange Act.